Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with... Read More

Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acceptance period has commenced and will end on May 13, 2024, at 24:00 hours CEST PLANEGG/MUNICH, Germany / Apr 11, 2024 / Business Wire / The Management Board... Read More

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the proposed acquisition of MorphoSys by Novartis AG ("Novartis"), following the expiration of the HSR Act waiting period. MorphoSys previously also announced the receipt of... Read More

Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value Sold all tafasitamab rights worldwide to Incyte Presented comprehensive Phase 3 MANIFEST-2 study results at ASH 2023 Annual Meeting, demonstrating pelabresib improves all four disease hallmarks of myelofibrosis Monjuvi ® U.S. net product sales of US$ 24.1 million (€ 22.4 million) for the fourth... Read More

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide... Read More

Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net product sales of 69% Anticipated 2024 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million Anticipated 2024 OpEx in the range of € 350 to 380 million and 2024 cash burn of approximately € 250 million (excluding debt and interest payments) Preliminary unaudited financial... Read More

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California. The company's Chief Financial Officer, Lucinda Crabtree, Ph.D., and Chief Research and Development Officer, Tim Demuth,... Read More

Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing symptom burden and a twofold increase in patients achieving both SVR35 and TSS50 versus placebo plus ruxolitinib Improved measures of anemia, including higher hemoglobin response rates, fewer patients requiring transfusions and fewer... Read More

MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%) The key secondary endpoints assessing symptom reduction, TSS50 and absolute change in TSS, showed significant improvements for intermediate-risk patients (p<0.05, p<0.02, respectively) and strong numerical improvements for overall population Pelabresib plus ruxolitinib showed clinically meaningful anemia improvement versus placebo and... Read More

Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023 Monjuvi® U.S. net product sales of US$ 23.4 million (€ 21.5 million) for the third quarter of 2023 U.S. FDA granted Fast Track designation for tulmimetostat in ARID1A-mutated endometrial cancer € 642.2 million in cash and other financial assets as of September 30, 2023 Conference call and webcast (in... Read More

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / November 9, 2023 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 pm GMT; 04:00 pm EST). MorphoSys' Management team will host a conference call and webcast on November 16, 2023, at 02:00 pm CET (01:00 pm GMT; 08:00 am EST) to present the results for the... Read More

Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2 Investor event focused on MANIFEST-2 with MorphoSys management and medical experts will be hosted onsite on Monday, December 11 Additional ASH 2023 presentations will highlight new findings from the Phase 2 MANIFEST study of pelabresib and clinical and preclinical studies of... Read More

Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million) Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65% Anticipate full year 2023 Monjuvi U.S. net product sales to be US$ 85-95 million and full year gross margin for Monjuvi U.S. net product sales to be approximately 75% MUNICH, GERMANY / ACCESSWIRE / October 25, 2023 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) today... Read More

Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company's third clinical program to receive Fast Track designation PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 12, 2023 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for tulmimetostat, the company's investigational next-generation dual inhibitor of EZH2 and... Read More

Monjuvi ® U.S. net product sales of US$ 23.6 million (€ 21.7 million) for the second quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023 Phase 3 studies frontMIND of tafasitamab in first-line diffuse large B-cell lymphoma and inMIND of tafasitamab in relapsed/refractory follicular lymphoma or marginal zone lymphoma are... Read More

Monjuvi ® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023 Enrollment of Phase 3 frontMIND study of tafasitamab in first-line diffuse large B-cell lymphoma is complete € 791.5 million in cash and other financial assets as of March 31, 2023... Read More

Conference Call Alert MUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on May 4, 2023 at 02:00 pm CEST (01:00 pm BST; 08:00 am EDT) to present the results for the first quarter 2023 and provide an outlook for... Read More

PLANEGG/MUNICH, Germany / Mar 15, 2023 / Business Wire / MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022. “2022 was a defining year for MorphoSys. We made advances in our pipeline by progressing our Phase 3 clinical trials, including pelabresib in myelofibrosis and tafasitamab in lymphomas. We also out-licensed highly promising, early and mid-stage product candidates,... Read More

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 9, 2023 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on March 16, 2023 at 01:00 pm CET (12:00 pm GMT; 8:00 am EDT) to present the results for the financial year 2022 and provide an... Read More

MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) (the " Company ") today announces that it will stop work and operations on its pre-clinical research programs to optimize its cost structure. As a result, MorphoSys will reduce its workforce at the Company's headquarters in Planegg, Germany, by approximately 17%. While the data from these pre-clinical programs are promising, MorphoSys would... Read More

MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure. While the data from these pre-clinical programs are promising, MorphoSys would need to make substantial investments to bring these programs into the clinic. As a result, MorphoSys will reduce its workforce at the... Read More

MUNICH, GERMANY / ACCESSWIRE / January 9, 2023 / MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study - a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis - are expected to be available in early 2024. The company previously... Read More

Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million) Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million Preliminary unaudited financial liability from the collaboration with Incyte of approximately € 220 million which represents a reduction of € 360 million MUNICH, GERMANY / ACCESSWIRE / January 5, 2023 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) today reported... Read More

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 28, 2022 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) publishes its financial calendar dates for the year 2023: Publication of Interim Statement / Report Conference Call Year-End Results 2022 March 15, 2023 // 9:00 pm CET (4:00 pm EDT; 8:00 pm GMT) March 16, 2023 // 1:00 pm CET (8:00 am EDT; 12:00 pm GMT) First Quarter Interim Statement 2023 May 3, 2023 // 10:00 pm CEST (4:00 pm... Read More